SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire & inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

401JK is trending strongly as its staking program sees significant adoption, with a substantial portion of tokens now locked, which the community views as a bullish indicator. Holders are rallying around its unique narrative as a 'pure belief asset' offering an alternative to traditional retirement plans, fueling widespread conviction.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after securing FDA approval for NEREUS, marking the first new motion sickness treatment in decades. The community is highly focused on the drug's significant potential beyond motion sickness, particularly its ability to address nausea associated with GLP-1 weight loss medications, which could unlock a massive market. Investors are actively discussing whether the current valuation fully reflects this pivotal regulatory success and the company's broader pipeline.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is currently trending due to its exceptionally low public float and high insider ownership, drawing intense comparisons to recent high-flying SPACs like AFJK. The community is highly bullish, anticipating significant price appreciation as a potential business combination announcement approaches for this US-based SPAC. Traders are actively discussing its potential for explosive moves driven by supply scarcity, aligning with patterns observed in other low-float market plays.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing high volatility as investors await an overdue FDA decision on Relacorilant for Cushing's syndrome, a key PDUFA date that passed without official news. This has ignited intense community debate, with some highlighting strong GRACE trial data and the broader pipeline, while others express concern that the delay may indicate a Complete Response Letter amidst notable trading volume and market speculation.

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

Aimei Health Technology Co Ltd (AFJK) is trending as traders speculate on a classic "China IPO squeeze" due to its notably low float and thin share structure. The community is actively discussing its highly volatile, casino-like movements, frequent trading halts, and comparing its potential for rapid price swings to similar recent Chinese tickers.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending amidst mixed analyst sentiment driven by concerns over crypto trading volumes, despite a strong 2025 performance. The community is buzzing with frustration over app glitches and modest rewards from recent holiday giveaways, fueling discussions about the platform's reliability and marketing approach. Investors are keenly watching how its crypto correlation and new ventures like prediction markets will shape its near-term outlook.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as investors eagerly await an FDA decision on its AXS-05 supplemental NDA for Alzheimer's disease agitation, viewed as a significant catalyst for an underserved market. This anticipation is fueled by consistently strong and growing prescription numbers for Auvelity in major depressive disorder, reflecting robust commercial execution. The company's expanding CNS pipeline and positive analyst sentiment continue to reinforce its perceived long-term value within the biopharmaceutical sector.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending amid a contentious and repeatedly postponed shareholder vote on increasing authorized shares, sparking intense debate over its future funding and growth strategy. Bulls anticipate significant, often classified, government contracts and strategic benefits from the Ask Sage acquisition, viewing current price movements as short-term manipulation. Conversely, skeptics express frustration with management, citing a lack of tangible contract announcements and fearing potential dilution, leading to a polarized community discussion.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf (WULF) is trending amidst diverse community sentiment following its successful closing of a $1.3 billion project-level financing for a major AI/HPC data center, an event bulls view as a strong validation of its strategic pivot. While supporters see this and recent zoning approvals as foundational for future growth and a buying opportunity, others express frustration over persistent price weakness, attributing it to broader market volatility and perceived manipulation.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is currently experiencing a surge in attention fueled by high expectations for its upcoming earnings report, with the community anticipating strong revenue growth driven by its high-margin drug Recorlev. Investors are also keenly focused on the company's pathway to sustained profitability and the long-term potential of its pipeline, particularly the promising XP-8121, which analysts believe could achieve blockbuster status. This positive outlook is supported by recent analyst target upgrades and a perceived de-risked profile, positioning Xeris for significant growth within the biopharma sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors

Altai Capital Management, L.P. (Altai), one of the largest shareholders and beneficial owners of approximately 5.2% of the outstanding common stock of OraSure Technologies, Inc. (OraSure or the...

Systematic Financial Management LP Increases Holdings in OraSure Technologies, Inc. $OSUR

Systematic Financial Management LP grew its position in OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 35.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The...

Private Management Group Inc. Has $16.38 Million Holdings in OraSure Technologies, Inc. $OSUR

Private Management Group Inc. grew its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 23.6% in the 2nd quarter, according to the company in its most recent Form 13F...

Stephens Lowers OraSure Technologies (NASDAQ:OSUR) Price Target to $3.00

Stephens lowered their target price on shares of OraSure Technologies from $3.50 to $3.00 and set an "equal weight" rating on the stock in a research note on Wednesday...

Acadian Asset Management LLC Lowers Position in OraSure Technologies, Inc. $OSUR

Acadian Asset Management LLC lowered its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 20.4% during the second quarter, according to the company in its most recent...

OraSure Technologies (NASDAQ:OSUR) Posts Earnings Results

OraSure Technologies (NASDAQ:OSUR - Get Free Report) issued its earnings results on Wednesday. The medical instruments supplier reported ($0.17) EPS for the quarter, missing the consensus estimate of...

OraSure Technologies (OSUR) Reports Q3 Loss, Lags Revenue Estimates

OraSure (OSUR) delivered earnings and revenue surprises of +18.75% and -7.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

InfuSystems Holdings, Inc. (INFU) Tops Q3 Earnings Estimates

InfuSystems Holdings (INFU) delivered earnings and revenue surprises of +37.50% and -1.91%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Tilray Brands, Inc. (TLRY) Reports Break-Even Earnings for Q1

Tilray Brands (TLRY) delivered earnings and revenue surprises of +100.00% and +1.29%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?

Altai Capital Management is reportedly preparing to launch a board fight at medical device company OraSure Technologies (OSUR).The hedge fund is one of the biggest owners of OraSure and built up its stake from 3% at the end of June to 5% in recent weeks, Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/transactional/altai-capital-lays-groundwork-board-fight-orasure-technologies-sources-say-2025-09-09/">reported</a>, citing two people familiar with the matter.The larger stake allows Altai to press its case for board representation more forcefully, the people told Reuters. Two OraSure directors will stand for reelection at next year's annual meeting, and Altai is likely to nominate two candidates, including its founder, Rishi Bajaj, at some point, the report stated. Bajaj last year suggested that an investor with experience in capital allocation should join the OraSure board, the sources told Reuters.Shares of the company traded 2% higher at the time of writing. On Stocktwits, retail sentiment regarding <a href="https://stocktwits.com/symbol/OSUR">OSUR stock</a> remained in ‘bearish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:573/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_12_44_48_PM_png_7a065a0f80.webp" alt="OSUR's Sentiment Meter and Message Volume as of 12:45 p.m. ET on Sept. 9, 2025 | Source: Stocktwits" width="573" height="62"><figcaption>OSUR's Sentiment Meter and Message Volume as of 12:45 p.m. ET on Sept. 9, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes it’s ‘good news’.<stembedurl>https://stocktwits.com/Gantz7/message/627948069</stembedurl>However, another user cheered for the Altai founder.<stembedurl>https://stocktwits.com/AnonMav/message/627979684</stembedurl>Last month, Reuters reported that OraSure Technologies (OSUR) received a letter from healthcare entrepreneur Ron Zwanziger stating that he may pursue a more "adversarial path" if the board continues to resist his offer to buy the company.Zwanziger made an unsolicited all-cash offer to buy OraSure for between $3.50 and $4.00 a share in June but was rebuffed. The entrepreneur stated in his letter that other investors have grown concerned and reached out to him."If the board is not willing to entertain a collaborative discourse, we will be left with no choice but to consider all alternatives available," the letter <a href="https://stocktwits.com/news-articles/markets/equity/orasure-receives-warning-from-ron-zwanziger/chssxJ9RdS9">said</a>, without detailing the alternative options. "We would prefer to work together with you in a collaborative fashion to realize the full value potential for all shareholders, rather than pursuing a more adversarial path," the letter stated, as per the report. However, Altai and Zwanziger are not working together, Reuters said on Tuesday.For the three months through the end of June, OraSure’s total net revenues fell 43% year-on-year to $31.24 million, while diluted and adjusted loss per share stood at $0.19 compared to a profit of $0.08 in the corresponding quarter of 2024.OSUR stock is down 8% this year and approximately 21% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gary-black-expects-tesla-q3-deliveries-to-exceed-wall-street-estimates-but-sees-full-year-numbers-slip/chwK7ojRdtl">Gary Black Expects Tesla Q3 Deliveries To Exceed Wall Street Estimates But Sees Full-Year Numbers Slip: Retail’s Divided On Stock Performance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Hedge Fund Reportedly Prepares To Launch Board Fight At OraSure Technologies: Retail Investors Believe It’s Good News

Altai Capital Management is one of the largest owners of OraSure and has increased its stake from 3% at the end of June to 5% in recent weeks, in an effort to press for board representation, Reuters reported.  

Equity

Altai Capital Management is one of the largest owners of OraSure and has increased its stake from 3% at the end of June to 5% in recent weeks, in an effort to press for board representation, Reuters reported.  


OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offers oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in 2000 in and is headquartered in Bethlehem, PA.

Current Price	$2.47
Prev Close	$2.43
Open	$2.44
Dividend Yield	0.00%
50-Day Moving Average	$2.51
Beta	1.11
Avg. Volume	813,835.79
PE Ratio	-3.05

52-Week High	$4.22
52-Week Low	$2.08
Market Capitalization	$174.31M
EPS (Annual)	-$0.262
Price to Book	0.49
Revenue Per Employee	$370,912.18
Enterprise Value/EBITDA	N/A

OSUR
Orasure Technologies Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OSUR News

OSUROrasure Technologies Inc.